공고 • Jun 02
Defence Therapeutics Inc. Appoints Dr. John Lambert as Board Director, Effective 1 June 2026 Defence Therapeutics Inc. announced the appointment of Dr. John Lambert to its Board of Directors, effective immediately,1 June 2026. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), further strengthening Defence's strategic capabilities as the Company advances its ACCUM-enabled ADC platform and partnership programs. Dr. Lambert is internationally recognized as one of the leading experts in the ADC field. He previously served in multiple senior scientific and executive leadership roles at ImmunoGen, including Chief Scientific Officer, Executive Vice President of Research, and member of the Executive Committee. During his tenure, scientists at ImmunoGen developed ADC technologies that ultimately contributed to the Genentech/Roche therapy KADCYLA, approved in 2013 for HER2-positive breast cancer. The company also discovered the anti-CD38 antibody that became Sanofi's SARCLISA and advanced several ADC molecules into clinical development, including ELAHERE, approved for platinum-resistant ovarian cancer. ImmunoGen was subsequently acquired by AbbVie in 2024. Prior to joining ImmunoGen in 1987, Dr. Lambert was among the first scientists recruited to the Dana-Farber Cancer Institute at Harvard Medical School to work on ImmunoGen-funded programs dedicated to developing ADCs and immunotoxins as anti-cancer therapeutics, at a time when the field was still in its infancy. Dr. Lambert's scientific career also includes training at some of the world's most respected academic institutions. He graduated from Christ's College, University of Cambridge (UK), with a degree in Natural Sciences before earning a Ph.D. in Biochemistry from the University of Cambridge in 1976, where he worked on the structure of glycolytic enzymes under the supervision of Professor Richard N. Perham. He subsequently completed postdoctoral research at the University of California, Davis, focusing on ribosome structure, and later at the University of Glasgow, Scotland, where he worked on the arom multienzyme complex. Since 2018, Dr. Lambert has advised numerous biotechnology companies and venture capital firms on ADC technologies, development strategies, and translational programs. He is the author or co-author of more than 130 peer-reviewed scientific publications and was elected Fellow of the American Institute for Medical and Biological Engineering (AIMBE) in 2016. 공고 • Oct 08
Defence Therapeutics Inc., Annual General Meeting, Dec 10, 2025 Defence Therapeutics Inc., Annual General Meeting, Dec 10, 2025. Location: quebec, montreal Canada 공고 • Aug 23
Defence Therapeutics Inc. announced that it expects to receive CAD 1.2 million in funding Defence Therapeutics Inc. announced a non-brokered private placement to issue 1,200 debentures units at an issue price of CAD 1,000 per unit for gross proceeds of CAD 1,200,000 on August 22, 2025. Each unit will consist of one CAD 1,000 principal amount of 8% convertible debenture and 1,666 common share purchase warrants. The debentures will bear interest at 8% per annum and will mature two years following the issue date. The debentures are unsecured. The principal amount of each debenture will be convertible at the option of the holder into common shares in the capital of the company at the conversion price of CAD 0.60 per common share. Each warrant will be exercisable to acquire one common share at an exercise price of CAD 0.75 per warrant share for a period of two years from the issue date. All securities issued in connection with the offering will be subject to a statutory hold period of four months and one day following the closing date of the offering in accordance with applicable securities legislation. Completion of the offering is subject to a number of conditions, including, but not limited to, the receipt of all regulatory approvals. The company may pay a finder's fee in connection with the offering to eligible arm's length finders in accordance with the policies of the Canadian Securities Exchange. 공고 • Mar 26
Defence Therapeutics Inc. Appoints Elias Theodorou as Chief Operating Officer, Effective April 2025 Defence Therapeutics Inc. announced that Dr. Elias Theodorou is joining the management team as the chief operating officer "COO", effective in April 2025. Dr. Elias Theodorou, Ph.D., is a molecular biologist with over 25 years of experience in cancer research, stem cell differentiation, and gene delivery. He is the co-founder of Protos Biologics Inc., where he has been developing innovative DNA delivery systems. Previously, he served as the Director of Research at WBC Biosciences LLC, where he co-invented a method to modify innate immune cells for enhanced anticancer properties. Dr. Theodorou earned his Ph.D. from Yale University, focusing on identifying novel drivers of neural differentiation. He has authored numerous publications and holds patents related to gene therapy and protein engineering. 공고 • Jan 01
Defence Therapeutics Inc. announced that it expects to receive CAD 4.2 million in funding Defence Therapeutics Inc. announced a non brokered private placement to issue 7,000,000 units at an issue price of CAD 0.60 per unit for gross proceeds of CAD 4,200,000 on December 31, 2024. Each Unit is comprised of one common share and one common share purchase warrant. Each Warrant will entitle the holder thereof to acquire one additional common share at a price of CAD 0.75 per common share for a period of 24 months of the closing date. The Company may pay a finder's fee in connection with the Offering in accordance with the policies of the CSE. The securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day following the closing date in accordance with the CSE. 
